Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 10/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9877388 | 0.91 | FKBP1A (0.49) | FKBP1ATSHRACEMEN1KMT2A | |
| SCHEMBL9878033 | 0.91 | FKBP1A (0.49) | FKBP1ATSHRACEMEN1KMT2A | |
| SCHEMBL9775235 | 0.89 | ALDH1A1 (0.50) | FKBP1ATSHRACEMEN1KMT2A | |
| SCHEMBL19955370 | 0.88 | FKBP1A (0.51) | FKBP1ATSHRACEMEN1KMT2A | |
| SCHEMBL13609888 | 0.88 | FKBP1A (0.51) | FKBP1ATSHRACEMEN1KMT2A | |
| SCHEMBL9775269 | 0.87 | ACE (0.46) | FKBP1ATSHRACEMEN1KMT2A | |
| SCHEMBL11086011 | 0.85 | FKBP1A (0.52) | FKBP1ATSHRACEMEN1KMT2A | |
| SCHEMBL10520643 | 0.85 | FKBP1A (0.52) | FKBP1ATSHRACEMEN1KMT2A | |
| SCHEMBL15457809 | 0.85 | FKBP1A (0.46) | FKBP1ATSHRACEMEN1KMT2A | |
| SCHEMBL9774191 | 0.85 | PREP (0.47) | FKBP1AACEMEN1KMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8937150-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2015-01-20 | — | — | US | disclosed |
| US-20120004196-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004196-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | FKBP1A 2526/4885TSHR 4834/4885ACE 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.